Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
As a consequence of YF outbreaks that hit Brazil, Argentina, and Paraguay in 2008-2009, a significant demand for YF vaccination was subsequently observed in Argentina, a country where the usual vaccine recommendations are restricted to provinces that border Brazil, Paraguay, and Bolivia. The goal of this paper is to describe the adverse events following immunization (AEFI) against YF in Argentina during the outbreak in the northeastern province of Misiones, which occurred from January 2008 to January 2009. During this time, a total of nine cases were reported, almost two million doses of vaccine were administered, and a total of 165 AEFI were reported from different provinces. Case study analyses were performed using two AEFI classifications. Forty-nine events were classified as related to the YF vaccine (24 serious and 1 fatal case), and 12 events were classified as inconclusive. As the use of the YF 17D vaccine can be a challenge to health systems of countries with different endemicity patterns, a careful clinical and epidemiological evaluation should be performed before its prescription to minimize serious adverse events.
Programa Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Argentina. Electronic address: cristianbiscayart@hotmail.com.
Cristián
C
Biscayart
Programa Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Argentina.
María Eugenia Pérez
ME
Carrega
Programa Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Argentina.
Sandra
S
Sagradini
Sociedad Argentina de Pediatría, Argentina.
Angela
A
Gentile
Sociedad Argentina de Infectología, Argentina.
Daniel
D
Stecher
Sociedad Latinoamericana de Medicina del Viajero, Argentina.
Tomás
T
Orduna
Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, Argentina.
Silvia
S
Bentancourt
Pan American Health Organization, Argentina.
Salvador García
SG
Jiménez
Sanatorio Británico, Rosario, Argentina.
Luis Pedro
LP
Flynn
Sanatorio Rivadavia, San Luis, Argentina.
Gabriel Pirán
GP
Arce
Dirección Provincial de Promoción y Prevención de la Salud, Provincia de Santa Fe, Argentina.
María Andrea
MA
Uboldi
Dirección Provincial de Promoción y Prevención de la Salud, Provincia de Santa Fe, Argentina.
Laura
L
Bugna
Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui", Pergamino, Argentina.
María Alejandra
MA
Morales
Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui", Pergamino, Argentina.
Clara
C
Digilio
Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui", Pergamino, Argentina.
Cintia
C
Fabbri
Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui", Pergamino, Argentina.
Delia
D
Enría
Programa Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Argentina.
Máximo
M
Diosque
Programa Nacional de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Argentina.
Carla
C
Vizzotti
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000368:Aged; D000369:Aged, 80 and over; D001118:Argentina; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D014611:Vaccination / Q000009:adverse effects*; D022341:Yellow Fever Vaccine / Q000009:adverse effects*; D055815:Young Adult
D022341:Yellow Fever Vaccine
Argentina; Safety; Severe adverse events; Yellow fever vaccine